drugset / Trial / NCT03780465
A Study of Safety and Tolerability of NOX66 in Healthy Volunteers
RandomizedSequentialTriple-blindTreatment
Summary
A Phase 1, double- blinded, randomised, placebo-controlled study to assess safety, tolerability and pharmacokinetics of 2 formulations of NOX66 in healthy subjects when administered over 4 cohorts as single NOX66 dose of 400 mg and 600 mg in comparison to single oral dose of 400 mg idronoxil.
Timeline
- Start
- 2019-03-01
- Primary completion
- 2019-03-01
- Completion
- 2019-03-01
Outcome
Outcome not reported
Stopped: “Decision to obtain PK data at a later date”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | idronoxil | Small molecule | 400 mg | Oral |
| Subject | idronoxil | Small molecule | 400 mg | Rectal |
| Subject | idronoxil | Small molecule | 600 mg | Rectal |
Indications
No indication recorded.